Clinical Trials
8 trialsNCT06860971 2025-12-31
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT01321554 2023-06-22
SELECT
Eisai Inc.
Phase 3 Completed
NCT00704730 2021-04-20
EXAM
Exelixis
Phase 3 Completed
NCT00984282 2018-09-13
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Bayer
Phase 3 Completed
NCT00196729 2015-03-18
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Sanofi
Phase 3 Completed
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn